Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease

American Journal of Medicine

Volumn 112, Issue 2, 2002, Pages 126-134

  Halkin, Amir ^a,b   Keren, Gad ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CATHEPSIN; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SIMVASTATIN; TRANDOLAPRIL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FIBRINOLYSIS; HEART DEATH; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

EID: 0037083088     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)01001-4     Document Type: Article

References (94)

1. Atherosclerosis: An inflammatory disease
2. Molecular bases of the acute coronary syndromes
3. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases
4. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation
5. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: The potential role of transcription factor NF-kappaB
6. Increased activity of nuclear factor-kappaB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats
7. Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris
8. Angiotensin induces inflammatory activation of human vascular smooth muscle cells
9. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor
10. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis
11. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats
12. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease
13. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins
14. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats
15. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability
16. Elevated levels of interleukin-6 in unstable angina
17. Induction of human lymphocyte migration by interleukin-3, interleukin-4, and interleukin-6
18. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line
19. Interleukin-6 family of cytokines and gp 130
20. Expression of intracellular adhesion molecule 1 in rat vascular smooth muscle cells by proinflammatory cytokines
21. Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: A placebo-controlled study in healthy volunteers
22. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone
23. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
24. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats
25. Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II
26. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats
27. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress
28. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells, and increases soluble ICAM-1 release in vivo
29. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis
30. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells
31. Bradykinin-induced vasodilation of human coronary arteries in vivo: Role of nitric oxide and angiotensin-converting enzyme
32. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells
33. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
34. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
35. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
36. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
37. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
38. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) study. Acute Infarction Ramipril Efficacy
39. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure: A report from the AIRE Study Investigators
40. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) study group
41. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
42. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials
43. Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits
44. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: Role of nitric oxide, prostanoids, oxidant stress, and bradykinin
45. Captopril and L-arginine have a synergistic cardioprotective effect in ischemic-reperfusion injury in the isolated rat heart
46. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure
47. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus
48. Improvement of coronary flow reserve after long-term therapy with enalapril
49. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: A multicenter study
50. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction
51. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells
52. Angiotensin II signal transduction in vascular smooth muscle: Role of tyrosine kinases
53. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts
54. Enalapril improves arterial elastic properties in rats with myocardial infarction
55. Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats
56. Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats
57. Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIa in early postmyocardial infarction stage
58. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells
59. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta
60. Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by captopril and reduced thiols
61. Regression of early atherosclerosis in hyperlipidemic hamsters induced by fosinopril and captopril
62. Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril
63. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: Effects of enalapril
64. Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits. II: Effect on regression of atherosclerosis and restoration of endothelial function
65. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet
66. Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits. I: Effect on progression of atherosclerosis and endothelial dysfunction
67. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice
68. Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin
69. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease: PART-2 Collaborative Research Group. Prevention of atherosclerosis with ramipril
70. Long-term effects of cholesterol lowering, and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril coronary atherosclerosis trial
71. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE)
72. Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients
73. The interrelation between carotid, femoral and coronary artery disease
74. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation
75. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril
76. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind placebo-controlled trial
77. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet
78. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
79. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA)
80. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design)
81. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure
82. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease
83. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure
84. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
85. The sixth report of the Joint National Committee on prevention detection, evaluation, and treatment of high blood pressure
86. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
87. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials
88. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition
89. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
90. Aspirin and ACE-inhibitors: For wedding or funeral?
91. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease
92. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
93. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: ACE inhibitors in the management of congestive heart failure: Comparative economic data
94. Evidence-based medicine: An incomplete method for informing treatment choices